Develops drugs for brain cancer.
Jun 2025Revenue A$42.0K/yrExpenses A$22.5M/yr
No trend
Figures by year
When will Kazia Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2025, revenue was A$42.0K and expenses A$22.5M.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Jun 2025 | A$42.0K | A$22.5M | −A$22.4M |
| Jun 2024 | A$2.31M | A$29.4M | −A$27.0M |
| Jun 2023 | A$0.00 | A$20.7M | −A$20.7M |
| Jun 2022 | A$0.00 | A$25.4M | −A$25.4M |
| Jun 2021 | A$15.2M | A$24.1M | −A$8.90M |
| Jun 2018 | A$119K | A$6.46M | −A$6.34M |
| Jun 2017 | A$249K | A$11.1M | −A$10.9M |
| Jun 2016 | A$406K | A$12.6M | −A$12.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.